HIF1 alpha Antibody

Overview

HIF1 alpha Antibody is a research-use primary antibody intended for detection of HIF1 in experimental workflows. It is supplied in Purified format. Key antibody attributes include Mouse, Monoclonal (mouse origin), clone HIF1A-84, isotype Mouse IgG2b, kappa. Applications listed for this product include FACS, IF. Reported/annotated localization context: Nuclear, possible cytoplasmic. Species reactivity (as provided): Human.

Key elements and design rationale

• Target: HIF1 (HIF1 alpha) — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.
• Format: Purified — format can influence background, multiplexing compatibility, and downstream detection strategies.
• Antibody identity: Mouse, Monoclonal (mouse origin), clone HIF1A-84, isotype Mouse IgG2b, kappa — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.
• Localization: Nuclear, possible cytoplasmic — expected subcellular distribution can guide band/structure interpretation and help flag off-target signal.
• Product notes (from provided description): HIF1 (hypoxia-inducible factor 1), a heterodimeric transcription factor complex central to cellular response to hypoxia, consists of two subunits (alpha and beta) which are basic helix-loop-helix proteins of the PAS (Per, ARNT, Sim) family. Expression of HIF-1 alpha is regulated by cellular oxygen level alterations as well as in oxygen-independent manner via different cytokines (through the PI3K-AKT-mTOR pathway), growth factors, oncogenic activation, or loss of tumor suppressor function etc. In normoxic cells, HIF-1 alpha is proline hydroxylated leading to a conformational change that promotes its binding to the VLH (von Hippel Lindau) protein E3 ligase complex; ubiquitination and followed by rapid proteasomal degradation. Hypoxia as well as chemical hydroxylase inhibitors (desferrioxamine, cobalt etc.) inhibit HIF-1 alpha degradation and lead to its accumulation in the cells, whereas, contrastingly, HIF-1 beta/ARNT (AhR nuclear translocator) remains stable under both conditions. Besides their critical role in hypoxic response, HIFs regulates the transcription of genes responsible for angiogenesis, erythropoiesis/iron-metabolism, glucose metabolism, cell proliferation/survival, adipogenesis, carotid body formation, B lymphocyte development and immune reactions.

Where multiple assay formats are possible, align the antibody format, host/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.

Biological background

In this catalog, HIF1 is positioned within Cell Signaling, Tumor research contexts. Localization annotations (e.g., Nuclear, possible cytoplasmic) can help contextualize expected signal patterns in imaging and fractionation-based readouts. For authoritative gene/protein nomenclature, domains/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.

Research relevance and current trends

• Higher-plex and spatially resolved readouts (e.g., multiplex IF/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host/isotype and labeling strategies.
• Genetic perturbation controls (knockout/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.
• Reproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.

Common research applications

• FACS: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
• IF: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
• Typical workflow themes: IF/ICC localization, Flow cytometry staining, ELISA binding assay, Specificity controls.
• Workflow notes: Detect HIF1 localization by IF/ICC in cultured cells (optimize fixation + dilution), Quantify HIF1-positive cells by flow cytometry in single-cell suspensions (include viability gate), Measure binding to HIF1 peptide/…

When comparing conditions, consistent sample processing and appropriate negative/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.

Notes for experimental interpretation

• Isoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.
• Species and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.
• Control concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic/orthogonal controls (e.g., KO/KD, independent antibodies, or RNA measurements) when feasible.

Monoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.